Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Understanding Your Stage and Subtype

At a Glance

Primary Cutaneous T-Cell Lymphoma (CTCL) staging uses the TNMB system to measure cancer in the skin, lymph nodes, internal organs, and blood. Staging determines if you have an early-stage subtype, like Mycosis Fungoides, or an advanced subtype, like Sézary Syndrome, which guides your treatment.

Staging is the process your medical team uses to describe the extent of your cancer. In Primary Cutaneous T-Cell Lymphoma (CTCL), staging is unique because it must account for the skin, lymph nodes, internal organs, and—critically—the blood [1][2].

The standard staging system for the most common types of CTCL is called TNMB [2].

Decoding the TNMB System

Each letter in TNMB represents a different “compartment” of your body. Doctors assign a number to each letter to show how much the cancer has spread [1].

T: Tumor (The Skin)

This measures how much of your skin is involved.
Note: A thickened, raised patch of skin is called a “plaque” and is common in early-stage disease. This is different from a literal “tumor” as defined in the T3 category.

  • T1: Limited disease. Patches or plaques cover less than 10% of your body surface area (roughly the size of 10 of your own palms) [2].
  • T2: Widespread disease. Patches or plaques cover 10% or more of your body [2].
  • T3: One or more deep, solid, nodular tumors are present on the skin [2].
  • T4: Generalized erythroderma, meaning the skin is red and scaly over 80% or more of the body [3][4].

N: Node (Lymph Nodes)

This indicates whether the lymphoma has moved into your lymph nodes. Doctors often use imaging (like CT or PET scans) or a physical exam to check for swelling [5][2].

M: Metastasis (Internal Organs)

This measures whether the cancer has spread to internal organs like the liver, lungs, or spleen. This is very rare in early-stage CTCL [1][2].

B: Blood (Circulating Cells)

In CTCL, the blood is considered a “compartment” where cancer cells can circulate. This is measured using a test called flow cytometry [6][7].

  • B0: No significant blood involvement [7].
  • B1: A low level of cancer cells (Sézary cells) is present in the blood [7].
  • B2: High blood tumor burden (>1,000 Sézary cells per microliter). This level of involvement is a hallmark of Sézary Syndrome [8][7].

Common Subtypes: MF vs. SS

The most common subtypes of CTCL are staged using this TNMB system, but they behave differently.

  • Mycosis Fungoides (MF): Usually begins as slow-growing patches or plaques. Most patients have early-stage disease (Stages IA-IIA), which is limited to the skin and carries a very favorable prognosis [9][10].
  • Sézary Syndrome (SS): This is considered an advanced-stage disease from the start. It is defined by widespread skin redness (erythroderma), swollen lymph nodes, and high blood involvement (B2 stage) [3][4].

Rare Subtype: pcALCL

Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) is a distinct, rare subtype. Unlike MF or SS, it usually presents as a single large tumor or a small cluster of nodules [3]. It is characterized by the presence of a specific protein called CD30 on more than 75% of the cancer cells [11][12].

Why Staging Matters

The distinction between early-stage (IA–IIA) and advanced-stage (IIB–IVB) is critical for your treatment plan [13][9]:

  • Early-Stage: Treatment is usually focused directly on the skin (light therapy, topical gels) to manage the rash and keep symptoms at bay [13][14].
  • Advanced-Stage: Because the cancer has moved into the nodes, blood, or organs, doctors usually introduce systemic therapies (medications that travel through the entire body) [15][16].

Important Note: Current guidelines have shifted toward using more objective blood measurements (flow cytometry) rather than manual counts, making staging more precise than in the past [17][7].

Common questions in this guide

What does the TNMB system stand for in CTCL staging?
The TNMB system evaluates four areas of the body: Tumor (skin involvement), Nodes (lymph nodes), Metastasis (spread to internal organs), and Blood. Doctors assign a number to each letter to indicate how far the lymphoma has spread.
What is the difference between Mycosis Fungoides and Sézary Syndrome?
Mycosis Fungoides is the most common subtype and usually starts as slow-growing skin patches or plaques. Sézary Syndrome is an advanced-stage disease characterized by widespread red skin (erythroderma), swollen lymph nodes, and high levels of cancer cells in the blood.
How does my CTCL stage affect my treatment options?
Early-stage CTCL is typically treated with skin-directed therapies like light therapy or topical gels to manage the rash. Advanced-stage disease usually requires systemic therapies, which are medications that travel throughout the entire body to treat the cancer in the blood or lymph nodes.
How do doctors measure blood involvement in CTCL?
Doctors use a specialized blood test called flow cytometry to accurately measure the number of circulating cancer cells, known as Sézary cells. This provides a more precise measurement than older manual counting methods.
What does a T1 or T2 score mean for my skin?
A T1 score means that patches or plaques cover less than 10% of your body surface area, which is roughly the size of ten of your palms. A T2 score indicates that the rash or plaques cover 10% or more of your body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my full TNMB score, including the 'B' (blood) category?
  2. 2.What percentage of my body surface area (BSA) is affected by the rash, and does that put me in the T1 or T2 category?
  3. 3.Based on my current stage, is the goal of treatment to manage symptoms or should we be looking at more systemic therapies?
  4. 4.Was my blood involvement tested using flow cytometry, and what was the absolute count of Sézary cells?
  5. 5.Does my report show any signs of 'large cell transformation' (LCT), and how does that affect my stage?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Management Strategies for Mycosis Fungoides in India.

    Raychaudhury T

    Indian journal of dermatology 2017; (62(2)):137-141 doi:10.4103/ijd.IJD_71_17.

    PMID: 28400632
  2. 2

    Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.

    Miyashiro D, Sanches JA

    Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.

    PMID: 37124514
  3. 3

    Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.

    Hague C, Farquharson N, Menasce L, et al.

    British journal of hospital medicine (London, England : 2005) 2022; (83(4)):1-7 doi:10.12968/hmed.2021.0149.

    PMID: 35506718
  4. 4

    Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

    Molloy K, Jonak C, Woei-A-Jin FJSH, et al.

    The British journal of dermatology 2020; (182(3)):770-779 doi:10.1111/bjd.18089.

    PMID: 31049926
  5. 5

    Coexistence of large cell transformed mycosis fungoides and diffuse large B-cell lymphoma in one patient.

    Rohan TZ, Suriano J, Tekmen V, et al.

    Journal of cutaneous pathology 2024; (51(10)):761-766 doi:10.1111/cup.14673.

    PMID: 38967043
  6. 6

    It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides.

    Craig FE

    Cytometry. Part B, Clinical cytometry 2021; (100(2)):125-128 doi:10.1002/cyto.b.21872.

    PMID: 32083391
  7. 7

    Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.

    Scarisbrick JJ, Hodak E, Bagot M, et al.

    European journal of cancer (Oxford, England : 1990) 2018; (93()):47-56 doi:10.1016/j.ejca.2018.01.076.

    PMID: 29477101
  8. 8

    A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.

    Vonderheid EC, Kantor GR, Telang GH, et al.

    Journal of cutaneous pathology 2019; (46(12)):913-924 doi:10.1111/cup.13564.

    PMID: 31403211
  9. 9

    Disseminated mature T-cell phenotype CD4/CD8 double-negative mycosis fungoides with pleural involvement.

    Kasinathan G, Sathar J

    Hematology, transfusion and cell therapy 2022; (44(4)):606-611 doi:10.1016/j.htct.2021.07.004.

    PMID: 34593365
  10. 10

    Cutaneous T cell lymphoma.

    Dummer R, Vermeer MH, Scarisbrick JJ, et al.

    Nature reviews. Disease primers 2021; (7(1)):61 doi:10.1038/s41572-021-00296-9.

    PMID: 34446710
  11. 11

    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.

    Henderson Berg MH, Davison K, Popradi G

    The British journal of dermatology 2022; (186(2)):379-381 doi:10.1111/bjd.20786.

    PMID: 34608632
  12. 12

    Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy.

    Mitteldorf C, Kampa F, Ströbel P, et al.

    Histopathology 2022; (81(1)):55-64 doi:10.1111/his.14660.

    PMID: 35403270
  13. 13

    Skin Directed Therapy in Cutaneous T-Cell Lymphoma.

    Tarabadkar ES, Shinohara MM

    Frontiers in oncology 2019; (9()):260 doi:10.3389/fonc.2019.00260.

    PMID: 31032224
  14. 14

    Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.

    Sanches JA, Cury-Martins J, Abreu RM, et al.

    Anais brasileiros de dermatologia 2021; (96(4)):458-471 doi:10.1016/j.abd.2020.12.007.

    PMID: 34053802
  15. 15

    Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.

    Duvic M

    Hematology. American Society of Hematology. Education Program 2015; (2015()):529-44 doi:10.1182/asheducation-2015.1.529.

    PMID: 26637769
  16. 16

    Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

    Horwitz SM, Scarisbrick JJ, Dummer R, et al.

    Blood advances 2021; (5(23)):5098-5106 doi:10.1182/bloodadvances.2021004710.

    PMID: 34507350
  17. 17

    Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.

    Olsen EA, Whittaker S, Willemze R, et al.

    Blood 2022; (140(5)):419-437 doi:10.1182/blood.2021012057.

    PMID: 34758074

This page explains CTCL staging and subtypes for educational purposes only. Always consult your oncologist or dermatologist for an accurate diagnosis and staging of your specific condition.

Get notified when new evidence is published on Primary cutaneous T-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.